Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.

Sugimoto, Kayo

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma. [electronic resource] - Oncology 2015 - 42-6 p. digital

Publication Type: Comparative Study; Journal Article

1423-0232

10.1159/000440630 doi


Adult
Aged
Aged, 80 and over
Antiviral Agents--therapeutic use
Carbamates
Carcinoma, Hepatocellular--epidemiology
Drug Therapy, Combination
Female
Follow-Up Studies
Genotype
Hepacivirus--drug effects
Hepatitis C, Chronic--blood
Humans
Imidazoles--therapeutic use
Interferon alpha-2
Interferon-alpha--therapeutic use
Isoquinolines--therapeutic use
Japan--epidemiology
Liver Neoplasms--epidemiology
Male
Middle Aged
Neoplasm Recurrence, Local--epidemiology
Neoplasm Staging
Oligopeptides--therapeutic use
Polyethylene Glycols--therapeutic use
Polymerase Chain Reaction
Prognosis
Pyrrolidines
RNA, Viral--genetics
Recombinant Proteins--therapeutic use
Ribavirin--therapeutic use
Simeprevir--therapeutic use
Sulfonamides--therapeutic use
Valine--analogs & derivatives
Viral Load
alpha-Fetoproteins--analysis